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Psychosis continuumConsiderable data support the phenomenological and temporal continuity between subclinical psychosis and
psychotic disorders. In recent years, neurocognitive deﬁcits have increasingly been recognized as a core feature
of psychotic illness but there are few data seeking to elucidate the relationship between subclinical psychosis
and neurocogntive deﬁcits in non-clinical samples. The goal of the present studywas to examine the relationship
between subclinical positive and negative symptoms, asmeasured by the Community Assessment of Psychic Ex-
periences (CAPE) and performance on the MATRICS Consensus Cognitive Battery (MCCB) in a large (n = 303)
anddemographically diverse non-clinical sample.We found that compared to participantswith low levels of sub-
clinical positive symptoms, participantswith high levels of subclinical positive symptomsperformed signiﬁcantly
better in the domains of working memory (p b .001), verbal learning (p = .007) and visual learning (p = .014).
Although comparison of participants with high and low levels of subclinical negative symptoms revealed no dif-
ferences inMCCB performance, we found that individuals with high levels of subclinical negative symptoms per-
formed signiﬁcantly better on ameasure of estimated IQ (WRAT-3 Reading subtest; p= .02) than thosewith low
levels of subclinical negative symptoms. These results are at odds with prior reports that have generally shown a
negative relationship between neurocognitive functioning and severity of subclinical psychotic symptoms, and
suggest some potential discontinuities between clinically signiﬁcant psychotic symptoms and sub-syndromal
manifestations of psychosis.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Considerable data support the phenomenological and temporal con-
tinuity between psychotic disorders and subclinical manifestations of
psychotic symptoms. Subclinical psychotic symptoms are common in
the general population with an estimated prevalence of 7.2% and an an-
nual incidence of 2.5% (Linscott and van Os, 2013). The continuity be-
tween subclinical psychosis and psychotic disorders is supported by
longitudinal studies demonstrating that high levels of subclinical psy-
chotic symptoms predate the onset of psychotic illness (Cannon et al.,
2002; Chapman et al., 1994; Fisher et al., 2013; Hanssen et al., 2005;
Poulton et al., 2000;Welham et al., 2009) aswell as studies demonstrat-
ing substantial overlap in genetic predisposition for clinical and subclin-
ical levels of psychotic symptoms (Kendler et al., 1993; Schulsinger,
1976; Tienari et al., 2003). Moreover, a recent review and meta-ital, North-Shore-Long Island
11004. Tel.: +1 718 470 8601;
Inc. This is an open access article unanalysis of the literature on subclinical psychosis spanning over 2 de-
cades (Linscott and van Os, 2013) found that nearly all of the demo-
graphic and experiential risk factors for psychotic disorders predicted
greater risk of subclinical psychosis.
Over the last several decades, deﬁcits across a range of cognitive
skills have increasingly been recognized as a core feature of psychotic
illness (e.g. Barch and Ceaser, 2012) but to date, only a limited number
of studies have examined whether similar deﬁcits are associated with
subclinical psychosis in non-clinical samples. Data derived from studies
of patients with schizotypal personality disorder (SPD), however, have
reported considerable overlap in the neurocogntive deﬁcits observed
in SPD relative to schizophrenia (SZ) (Siever and Davis, 2004 for a re-
view). Because SPD is believed to represent an underlying predisposi-
tion for SZ or “psychosis-proneness” (Claridge et al., 1996), these data
suggest that neurocogntive deﬁcits may be present across the lower
ends of the psychosis continuum.
Studies examining the relationship between subclinical psychosis
and neurocognitive functioning in non-clinical samples have yielded in-
consistent results and have been limited in terms of the cognitive do-
mains assessed (Giakoumaki, 2012). For example, Van Os et al. (2005)der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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associated with severity of overall levels of subclinical psychosis. How-
ever, these authors did not assess other domains of cognitive function.
Contrary to the sex effect reported by Van Os et al. (2005), Simons
et al. (2007) measured speed of processing and verbal learning in an
all female sample and found a signiﬁcant association between both
positive and negative subclinical symptoms and decreased speed of
processing. Laurent et al. (2001) examined only set-shifting with the
Wisconsin Card Sorting Test (WCST) and concluded that ﬁrst-degree
relatives of patients with SZwho had high scores of negative schizotypy
on the Chapman scales scored signiﬁcantly worse than relatives who
had low scores and worse than healthy controls. Finally, Barnett et al.
(2013) recently investigated whether childhood cognitive function
was associated with adult subclinical psychotic symptoms in a large
prospective birth cohort. They found that general cognitive ability
(g) assessed at age 8, 11 and 15 was signiﬁcantly predictive of subclin-
ical psychotic symptoms in middle age. Speciﬁcally, lower cognitive
scoreswere associatedwith a greater likelihood of endorsing subclinical
psychotic symptoms. In this study, however, the association between
current cognitive function and endorsement of subclinical psychotic
symptoms was not assessed.
Several limitations of the aforementioned studies should be noted.
First, most of these studies did not examine the effects of subclinical
positive and negative symptoms separately. Cross-sectionally, the rela-
tionship between symptom severity and cognitive impairment in pa-
tients with SZ suggests that negative symptoms are more closely
related to cognitive deﬁcits than positive symptoms (Harvey et al.,
2006). Thus, it is possible that themixedﬁndings on the relationship be-
tween subclinical psychosis and cognitive function are related, in part,
to the focus on overall levels of subclinical psychosis. Additionally, the
cognitive domains examined have been limited and do not provide a
comprehensive assessment of the relation between subclinical psycho-
sis and cognitive function across the full range of domains typically ob-
served to be impaired in SZ.
Thus, the goal of the present study was to examine this relationship
in a large and demographically diverse non-clinical sample comprehen-
sively characterized for the presence of subclinical psychotic symptoms
and comprehensively assessed for neurocogntive performance. Speciﬁ-
cally, we aimed to evaluate whether the presence of high levels of sub-
clinical positive or negative symptoms as measured by the Community
Assessment of Psychic Experiences (CAPE) (Stefanis et al., 2002) would
be associated with differential performance across the 7 neurocognitive
domains assessed by theMATRICS Consensus Cognitive Battery (MCCB)
(Kern et al., 2008).
2. Method
2.1. Participants
The present sample comprised 303 healthy adult volunteers (53.13%
female, 60.40% Caucasian,Mage = 38.12 ± 14.29 years,MIQ (based on
WRAT-3 Reading)=103.14± 8.43) recruited from the general popula-
tion via word of mouth, newspaper and internet advertisements and
posted ﬂyers for an NIMH-funded study of subclinical psychosis in the
general population (MH086756 to PD). Participants were excluded if
they had a past or present affective or psychotic disorder diagnosis, ac-
tive or recent substance abuse, or if they had a history of CNS trauma,
neurological disorder, or previously diagnosed learning disability.
2.2. Diagnostic assessments
Participantswere initially administered the Structured Clinical Inter-
view for the DSM-IV, Non-Patient edition (SCID-I/NP) to rule out a past
or present affective or psychotic disorder. Information obtained from
the SCIDwas compiled into a narrative case summary and lifetime diag-
nosis was determined by two senior members of the ZHH faculty.2.3. Assessment of subclinical psychosis
Participants were administered the Community Assessment of Psy-
chic Experiences (CAPE) (Stefanis et al., 2002), a 42-item, self-report
questionnaire that measures three dimensions of subclinical psychopa-
thology including positive, negative and depressive symptoms. In the
present study, the positive and negative frequency dimensionswere ex-
amined for relation to neurocogntive functioning. Consistent with prior
reports (van Os et al., 2009), the positive and negative subscale scores
derived from the CAPE were not normally distributed. Indeed, inspec-
tion of the data in our sample indicated that the CAPE subscale scores
produced a half-normal distribution. Thus, because standard statistical
techniques could not be utilized, we chose to dichotomize the subscale
scores to facilitate the use of parametric tests. Initially, scores were di-
vided into quartiles for both the negative and positive dimensions of
subclinical psychotic symptoms. Any participant with a score at or
above the 75th percentile was assigned to the high symptom group
while those falling below the 75th percentile were assigned to the low
symptom group. Thus, participants with a negative symptom subscale
score greater than 20, representing on average, a score 1.23 standard
deviations above the sample mean were considered to have high levels
of negative symptoms. This score is consistent with participants
experiencing several infrequent negative psychotic-like experiences or
experiencing 2–3 recurrent experiences. Participants with a raw posi-
tive symptom subscale score greater than 24, representing on average,
a score 1.10 standard deviations above the sample mean were consid-
ered to have high levels of positive symptoms. This score is consistent
with participants experiencing several infrequent positive psychotic-
like experiences or experiencing 1–2 recurrent experiences. It should
also be noted that the CAPE provides a measure of the distress associat-
ed with the experience of positive and negative subclinical symptoms.
In our data, these distress scores are highly correlatedwith the frequen-
cy scores (rho N .9). Thus, these data were not examined as we believed
they were redundant with analyses based on the frequency scores.
2.4. Neurocognitive assessment: the MCCB
To assess neurocognitive functioning, The MATRICS Consensus Cog-
nitive Battery (MCCB)was administered to all participants. TheMCCB is
comprised of 10 standardized cognitive measures that collectively cap-
ture functioning within seven cognitive domains that are reliably im-
paired in schizophrenia (Nuechterlein et al., 2004) including: Speed of
Processing, Attention/Vigilance, Working Memory, Verbal Learning,
Visual Learning, Reasoning/Problem-solving, and Social Cognition. Par-
ticipants in the current study completed the MCCB in one visit. In the
present study, T scores, corrected for age and sex, derived from the
MCCB scoring program were utilized as the primary dependent mea-
sures. Additionally, we utilized the Wide Range Achievement Test-
Third Edition-Reading Subtest (WRAT-3) as an estimate of IQ. The
WRAT-3 Reading subtest is a test that assesses single word reading
skill and is highly correlated with full scale IQ (Kremen et al., 2006).
2.5. Statistical analyses
We initially sought to rule out differences between participants with
high and low levels of symptoms on age, sex, race and estimated IQ
(based on WRAT-3 Reading subtest score). Thus, we utilized t-tests or
chi square tests, as appropriate, to examine the distributions of these
variables in those characterized as having high levels of positive symp-
toms vs. those with low levels of positive symptoms and in those char-
acterized as having high levels of negative symptom vs. those with low
levels of negative symptoms. Following these analyses, we carried out
two multivariate analyses of covariance (MANCOVAs) comparing the
high and low positive symptom groups and the high and low negative
symptoms groups on all 7MCCB domains. Because both race and gener-
al intelligence level have been shown to inﬂuence performance on the
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2014; Rushton and Jensen, 2005), racial group (white and non-white)
and WRAT-3 Reading subtest standard score were included as covari-
ates in these analyses. We did not include age and sex as covariates in
these analyses because the MCCB T scores used as the dependent mea-
sures were corrected for these demographic variables a priori using the
MCCB scoring program.
3. Results
Comparison of the high and low positive symptom groups revealed
no differences in age, sex, race or estimated IQ (all p’s N 0.19). These
data are shown in Table 1. The MANCOVA comparing the high and
low positive symptom group revealed a signiﬁcant overall effect
(F(7,260) = 4.68; p b 0.001) with post hoc tests indicating that par-
ticipants with high levels of positive symptoms scored signiﬁcantly
higher than participants with low levels of positive symptoms on work-
ingmemory (F(1,266)= 16.47; p b 0.001), verbal learning (F(1,266)=
7.40; p = 0.007) and visual learning (F(1,266) = 6.11; p = 0.014).
These data are shown in Fig. 1.
It should be noted that some of our participants (N= 42) were still
within the age range of risk for conversion to a psychotic disorder (i.e.
b30 years old), which could have implications for cognitive functioning.
Thus, to ensure that these results were not driven by a subset of partic-
ipants who could potentially transition to a psychotic disorder, we re-
moved participants under that age of 30 and re-ran the MANCOVA.
The results of this analysis were identical to the results obtained in the
full sample. Additionally, because negative symptoms are generally
highly correlated with positive symptoms in both clinical and non-
clinical samples (Linscott and vanOs, 2013),we followedup this analysis
by examining 1) the relation between positive and negative symptoms
subscale scores and 2) the effect of including the negative symptom
subscale score as a covariate in the original MANCOVA comparing the
high and low positive symptom groups. In these analyses, the positive
symptom and negative symptom subscales were highly correlated
(rho= .59; p b 0.001).Moreover, although theMANCOVA remained sig-
niﬁcant (F(7,259)=2.45; p=0.02), the post hoc tests indicated that the
difference between groups was no longer signiﬁcant in the visual learn-
ing domain. The differences in working memory and verbal learning
however, remained signiﬁcant (p = 0.004 and p = 0.03, respectively).
Finally, to conﬁrm that these ﬁndings were not an artifact of themethod
we used to dichotomize our sample, we also examined the correlations
between the raw CAPE positive symptom subscale score and T scores
for the workingmemory and verbal learning domain. These analyses in-
dicated the CAPE positive symptom subscale was positively correlated
with both working memory (rho = 0.14; p = 0.02) and verbal learning
(rho = 0.12; p = 0.04).
Comparison of the high and low negative symptom groups revealed
no differences in age, sex or race (all p’s N 0.38). Comparison of the high
and low negative symptom groups on our measure of estimated IQ,
however, indicated that participants with high levels of negative symp-
toms had signiﬁcantly betterWRAT-3 Reading subtest standard scoresTable 1
Participant demographics.
Symptom Domain Age (SD) % Female WRAT-3 (SD) % Minority
Positive Symptoms
High (N = 103) 37.91 (14.27) 48.54% 104.02(8.48) 44.66%
Low (N = 200) 38.53(14.40) 55.5% 102.68 (8.39) 37.00%
Negative Symptoms
High (N = 92) 38.91 (14.08) 53.26% 104.88 (7.41)a 35.87%
Low (N = 211) 37.77 (14.81) 53.08% 102.38 (8.74) 41.23%
Note: Scores for the Wide Range Achievement Test-Third Edition-Reading Subtest
(WRAT-3) are presented as standard scores.
a Participants classiﬁed as high on subclinical negative symptoms score signiﬁcantly
higher on theWRAT-3 than those classiﬁed as low on negative symptoms (t (300) = 2.38;
p = .02).than those participants who had low levels of negative symptoms
(t = 2.38, p = 0.02). These data are shown in Table 1. The MANCOVA
comparing the high and low negative symptom groups across the 7
MCCB domains revealed no signiﬁcant overall effect. These data are
shown in Fig. 2.
In the present sample of 303 participants 47 participants were clas-
siﬁed as high in both positive and negative subclinical symptoms. Com-
parison of these participants to those characterized as low in both
symptomdomains (N=150) using aMANCOVA identical to the prima-
ry analyses, revealed that those with high levels of both subclinical
positive and negative symptoms performed signiﬁcantly better in the
domains of working memory (p b 0.001) and visual learning (p =
.036) and trended toward better performance in the verbal learning
domain (p = 0.053).
Finally, to demonstrate that those in the high symptom groups
were exhibiting symptoms that could be considered clinically relevant,
we assessed a sample of stable outpatients with schizophrenia or
schizoaffective disorder (N = 184) recruited to an NIMH-funded
study of functional disability using the CAPE. We have previously dem-
onstrated that scores obtained on the CAPE in patient samples are valid
and converge with those derived from clinician-administered assess-
ment scales (DeRosse et al. 2014). Using this sample, which is well
matched in age and sex to the control sample in the present study, we
compared the raw CAPE scores in 1) our high positive symptom group
to patients scoring within the lower half of the distribution on the raw
CAPE positive symptom score and 2) our high negative symptom
group to patients with scoring within the lower half of the distribution
on the raw CAPE negative symptom score. In the positive symptom
analysis, the mean rank of the controls was signiﬁcantly higher than
the mean rank of the patients (mean rank controls = 121.89 vs. mean
rank patients = 75.22; p b 0.001). Similarly, in the negative symptom
analysis, the mean rank of the controls was signiﬁcantly higher than
the mean rank of the patients (mean rank controls = 119.58 vs. mean
rank patients= 50.00; p b 0.001). These data suggest that the symptom
levels experienced by participants characterized as having “high” sub-
clinical symptoms are very similar to the mild symptoms observed in
patients with psychotic disorders.
4. Discussion
The present ﬁndings suggest that high levels of positive subclinical
symptoms in participants with no history of an axis I psychotic or affec-
tive disorder are associated with signiﬁcantly better performance on
measures of working memory, verbal learning, and visual learning as
measured by the MCCB. Moreover, although no effect of high negative
symptoms was noted on MCCB performance, ancillary ﬁndings indicated
that those who scored high on negative symptoms evidenced signiﬁcantly
better performance on a measure of estimated IQ (WRAT-3 Reading
subtest). These results are at oddswith several prior reports that have gen-
erally shown a negative relationship between neurocognitive functioning
and severity of subclinical psychotic symptoms (Jabben et al., 2007;
Laurent et al., 2001; Simons et al., 2007; van Os et al., 2005).
Our ﬁndings suggest some potential discontinuities between clini-
cally signiﬁcant psychotic symptoms and sub-syndromal manifesta-
tions of psychosis. Speciﬁcally, if subclinical psychosis represents a
milder manifestation of the psychotic symptoms observed in disorders
such as SZ, wemight expect to see cognitive impairment in the individ-
uals exhibiting high levels of subclinical psychotic symptoms similar to,
albeit less severe than, those observed in SZ. Indeed, it has generally
been found that cognitive deﬁcits consistently accompany clinically sig-
niﬁcant psychotic symptoms (Bora et al., 2010; Lewandowski et al.,
2011; Simonsen et al., 2011). Contrary to this expectation, however,
we found better cognitive performance in individuals with high levels
of subclinical psychosis.
One possible explanation for this discrepancy is that symptom se-































































Fig. 1. Comparison of participants classiﬁed as high vs. low on subclinical positive psychotic symptoms across all 7MCCBDomains. Mean T scores have been adjusted for race andWRAT-3
performance. Signiﬁcant differences are indicated by an asterisk (*).
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ﬁndings that suggest higher cognitive capacities act as a resilience factor
against clinically signiﬁcant psychosis (Green, 1996; Green, Kern and
Heaton, 2004; Morrison et al., 2004). First, patients with higher a priori
cognitive capacities tend to have better functional outcomes than pa-
tients with lower cognitive capacities (Green, 1996; Green, Kern and
Heaton, 2004). Moreover, the risk of transitioning from a prodromal
state to a psychotic disorder is signiﬁcantly associated with impaired
neurocognitive function (Keefe et al., 2006). Thus, when considering
the population of individuals with high levels of subclinical psychosis,
those with low a priori cognitive capacities would be expected to tran-
sition to clinically signiﬁcant psychosis at a higher rate while those with
higher cognitive capacities would be expected to pool in comparatively
larger numbers in the subclinical domain because their high cognitive
capacities protect them from transitioning. If this is the mechanism at
work, then the results of the present study could be attributed to an
inherent sampling bias. This conclusion would also suggest that the
cognitive deﬁcits observed in psychotic disorders such as SZ may be in-
dependent from the positive and negative symptoms characteristic of
the illness. This is consistent with several lines of research suggesting
that psychotic and cognitive symptoms may be separable and perhaps
independent characteristics of SZ (see Harvey et al., 2006 for a review).
It is also possible, however, that there is a direct causative link be-
tween subclinical psychosis and increased cognitive function. Several
studies seeking to elucidate why psychosis continues to persist despite







































Fig. 2.Comparison of participants classiﬁed as high vs. low on subclinical negative psychotic sym
performance. No signiﬁcant differences were found for any of the MCCB domains.have proposed that genetic variants associated with subclinical psycho-
sis may be beneﬁcial in some way. Several studies have suggested that
some of the risk variants may be associated with heightened creativity
or other intellectual abilities (Batey and Furnham, 2008; Burch et al.,
2006; Claridge and Blakey, 2009; Green and Williams, 1999; Karlsson,
1970; Keefe andMagaro, 1980; Kéri, 2009;Miller and Tal, 2007). For ex-
ample, Karlsson (1970) found that patient relatives, but not the patients
themselves, had a signiﬁcantly higher probability of being persons
of eminence than people in the general population, and Green and
Williams (1999) reported that individuals with higher scores on a test
of schizotypy produced the most creative responses on a divergent
thinking battery.
Several limitations of the present study should be noted. First, be-
cause the scores obtained on the positive and negative symptom sub-
scales of the CAPE were not normally distributed, we opted to use an
extreme groups analysis (Preacher et al., 2005), which has some inher-
ent limitations. This approach may have limited our ability to detect
more nuanced relationships between the level of subclinical psychotic
symptoms and neurocognitive performance. Moreover, because partic-
ipants in the overall samplewere only excluded if theymet criteria for a
psychotic or mood disorder 16 participants met criteria for another axis
I disorder (4 anxiety disorder NOS, 12 past substance abuse). However,
to rule out the effects of these diagnoses on our ﬁndings we re-ran both
of the primary MANCOVAs. The results of these analyses were identical
to what was found in the larger sample suggesting that the observed




















ptoms across all 7MCCBDomains.Mean T scores have been adjusted for race andWRAT-3
179C. Korponay et al. / Schizophrenia Research: Cognition 1 (2014) 175–179axis I disorder. Despite these limitations, however, the present ﬁndings
contribute to a growing literature seeking to elucidate the relationship
between subclinical psychosis and neurocogntive functioning in other-
wise healthy adults. Additional studies in larger samples are warranted.
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